Gene editing in immune cells using fat-based nanoparticles for future immunotherapy

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Chantal PICHON reports financial support and equipment, drugs, or supplies were provided by Sanofi. Anne Galy reports financial support, article publishing charges, equipment, drugs, or supplies, and travel were provided by French National Research Agency. Michel Cogne reports financial support, article publishing charges, equipment, drugs, or supplies, and travel were provided by French National Research Agency. Catalina Bordeianu reports a relationship with Sanofi that includes: employment and equity or stocks. Nathalie Rameix reports a relationship with Sanofi that includes: employment and equity or stocks. Ivan Ciganek reports a relationship with Sanofi that includes: employment. Christophe Delehedde reports a relationship with Sanofi that includes: employment and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.